Supreme Court Maintains Access to Mifepristone in Unanimous Decision

The ruling preserves the availability of the abortion drug, with the court finding the plaintiffs lacked standing to challenge the FDA's approval.

The Supreme Court ruled 9-0 in favor of the FDA, keeping mifepristone accessible for medication abortions and miscarriage management.
The decision was based on procedural grounds, concluding that the plaintiffs did not have the standing to sue.
The FDA had removed several safety protocols for mifepristone in 2016, leading to the legal challenge.
Medical professionals played a significant role in framing the debate around safety and patient care.
Reproductive-justice advocates warn that future challenges to mifepristone's availability are likely.